We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Tamsulosin Phase III Clinical Trial -Double-Blind, Placebo Controlled Study in Female Patients With Lower Urinary Tract Syndrome

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00239265
First Posted: October 17, 2005
Last Update Posted: October 22, 2007
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
Astellas Pharma Inc
  Purpose
The purpose of this study is to determine whether Tamuslosin is effective in the treatment of lower urinary tract syndrome with female patients.

Condition Intervention Phase
Urinary Tract Diseases Drug: Tamuslosin Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double
Primary Purpose: Treatment

Resource links provided by NLM:


Further study details as provided by Astellas Pharma Inc:

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   20 Years to 90 Years   (Adult, Senior)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patients with urination disorder not accompanied by apparent organic or neurologic abnormality(lower urinary tract syndrome: LUTs).

Exclusion Criteria:

  • Patients with urination disorder accompanied by apparent organic or neurologic abnormality, active urinary tract infections, severe cardiovascular, hepatic and/or kidney complications.
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00239265


Locations
Japan
Chubu region, Japan
Chugoku region, Japan
Hokkaido region, Japan
Kinki region, Japan
Kyushu region, Japan
Touhoku region, Japan
Sponsors and Collaborators
Astellas Pharma Inc
Investigators
Study Chair: Study Director Clinical Development, Astellas Pharma Inc.
  More Information

ClinicalTrials.gov Identifier: NCT00239265     History of Changes
Other Study ID Numbers: B6171/LCT2
First Submitted: September 13, 2005
First Posted: October 17, 2005
Last Update Posted: October 22, 2007
Last Verified: October 2007

Keywords provided by Astellas Pharma Inc:
tamsulosin
urinary tract diseases
female

Additional relevant MeSH terms:
Urologic Diseases
Tamsulosin
Adrenergic alpha-1 Receptor Antagonists
Adrenergic alpha-Antagonists
Adrenergic Antagonists
Adrenergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs
Urological Agents